Angstrom Pharmaceuticals, Inc.

Solana Beach, CA 92075

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $510K
First Award Date 09/01/99
Most Recent Award Date 09/14/01

Key Personnel

Last Name Name Awards Contact
Jones Terence R Jones 2
Mazar Andrew P. Mazar 1

3 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-98-22
Budget: 09/14/01 - 07/31/04

We have developed a cyclic peptide (Angstroms 36) that potently inhibits the binding of urokinase plasminogen activator (uPA) to its receptor (uPAR). The binding of uPA to uPAR initiates several pathways (matrix remodeling, signal transduction) that lead to rumor cell invasion, angiogenesis and metastasis. We propose to evaluate Angstroms 36 ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-CA-98-22
Budget: 08/18/00 - 07/31/01

We have developed a cyclic peptide (Angstroms 36) that potently inhibits the binding of urokinase plasminogen activator (uPA) to its receptor (uPAR). The binding of uPA to uPAR initiates several pathways (matrix remodeling, signal transduction) that lead to rumor cell invasion, angiogenesis and metastasis. We propose to evaluate Angstroms 36 ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/99 - 02/28/01

An emerging paradigm is that fragments of plasma or extracellular proteins may regulate angiogenesis. A known plasma protein has recently been identified as having anti-angiogenic activity only after proteolytic activation. This protein has no homology to previously identified proteins with anti-angiogenic activity e.g. angiostatin, thrombospond...